| Assessment Status | Rapid Review Complete |
| HTA ID | 25046 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | Durvalumab is indicated in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer. |
| Assessment Process | |
| Rapid review commissioned | 25/07/2025 |
| Rapid review completed | 11/08/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab in combination with gemcitabine and cisplatin compared with the current standard of care. |